Targeted next generation sequencing screening of Lynch syndrome in Tunisian population.


Journal

Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 23 5 2019
medline: 4 12 2019
entrez: 23 5 2019
Statut: ppublish

Résumé

A high colorectal cancer (CRC) incidence is observed in Tunisia, with a relatively high proportion of patients developing CRC before the age of 40. While this suggests a genetic susceptibility, only a few Tunisian Lynch Syndrome families have been described. In this study we aimed to identify the underlying genetic cause in 32 patients with early onset CRC and/or a positive family history. Of twenty-four patients' tumor or biopsies could be analyzed with immunohistochemical staining to detect loss of expression of one of the MMR proteins. Ten tumors showed loss of expression, of which one tumor was from a patient where a germline pathogenic MSH2 variant was detected previously with Sanger sequencing. Next generation sequencing of the MMR, POLE and POLD1 genes was performed in leukocyte and tumor DNA of the remaining nine patients, as well as in two patients with MMR-proficient tumors, but with severe family history. In six of 11 patients a germline variant was detected in MLH1 (n = 5) or MSH2 (n = 1). Two of six patients were from the same family and both were found to carry a novel in-frame MLH1 deletion, predicted to affect MLH1 function. All MLH1 variant carriers had loss of heterozygosity with retention of the variant in the tumors, while a somatic pathogenic variant was detected in the patient with the germline MSH2 variant.

Identifiants

pubmed: 31114938
doi: 10.1007/s10689-019-00130-y
pii: 10.1007/s10689-019-00130-y
doi:

Substances chimiques

MLH1 protein, human 0
Poly-ADP-Ribose Binding Proteins 0
POLD1 protein, human EC 2.7.7.-
DNA Polymerase II EC 2.7.7.7
DNA Polymerase III EC 2.7.7.7
POLE protein, human EC 2.7.7.7
MSH2 protein, human EC 3.6.1.3
MutL Protein Homolog 1 EC 3.6.1.3
MutS Homolog 2 Protein EC 3.6.1.3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-348

Références

Nat Commun. 2014 Oct 13;5:5191
pubmed: 25307848
BMJ Open Gastroenterol. 2016 Dec 7;3(1):e000120
pubmed: 28074150
Cell. 1993 Dec 17;75(6):1215-25
pubmed: 8261515
Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169
pubmed: 27899622
J Pathol. 2014 Dec;234(4):548-59
pubmed: 25111426
Gastroenterology. 2018 Mar;154(4):897-905.e1
pubmed: 29146522
JAMA. 2005 Apr 27;293(16):1979-85
pubmed: 15855431
Ann Oncol. 2010 May;21 Suppl 5:v78-81
pubmed: 20555108
Clin Cancer Res. 2004 Feb 1;10(3):972-80
pubmed: 14871975
Clin Genet. 2012 Dec;82(6):534-9
pubmed: 22035446
Hum Mutat. 2010 Mar;31(3):247-53
pubmed: 20020535
Br J Cancer. 2007 May 21;96(10):1605-12
pubmed: 17453009
N Engl J Med. 2003 Mar 6;348(10):919-32
pubmed: 12621137
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5
pubmed: 9618505
JAMA Oncol. 2018 Jun 1;4(6):806-813
pubmed: 29596542
Nat Genet. 2013 Feb;45(2):136-44
pubmed: 23263490
Eur J Hum Genet. 2015 Aug;23(8):1080-4
pubmed: 25370038
Br J Cancer. 2014 Jul 29;111(3):598-602
pubmed: 24918813
J Pathol. 2013 Jun;230(2):148-53
pubmed: 23447401
Gastroenterology. 2014 Mar;146(3):643-646.e8
pubmed: 24333619
Exp Mol Pathol. 2013 Feb;94(1):121-5
pubmed: 22750048
Cancer Res. 2007 May 15;67(10):4595-604
pubmed: 17510385
Eur J Hum Genet. 2016 Jul;24(7):1089-92
pubmed: 26648449
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Curr Opin Genet Dev. 2014 Feb;24:107-13
pubmed: 24583393
Asian Pac J Cancer Prev. ;18(10):2733-2739
pubmed: 29072401
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Nucleic Acids Res. 2004 Oct 08;32(18):5321-38
pubmed: 15475387
Int J Colorectal Dis. 2011 Apr;26(4):455-67
pubmed: 21311894
Nature. 1994 Sep 1;371(6492):75-80
pubmed: 8072530
Hum Mol Genet. 2001 Apr;10(7):735-40
pubmed: 11257106
Nat Genet. 2009 Jan;41(1):112-7
pubmed: 19098912
Genes Chromosomes Cancer. 2004 Jul;40(3):261-5
pubmed: 15139004

Auteurs

Rihab Ben Sghaier (R)

Cytogenetic, Molecular Genetics and Human Reproduction Biology - Farhat, HACHED Hospital, Sousse, Tunisia. Rihab28biologiste@gmail.com.

Anne Maria Lucia Jansen (AML)

Pathology Department, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.

Ahlem Bdioui (A)

Cytology and Anatomopathology Department, Farhat HACHED Hospital, Sousse, Tunisia.

Tom Van Wezel (T)

Pathology Department, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.

Mehdi Ksiaa (M)

Gastroenterology Department, Sahloul Hospital, Sousse, Tunisia.

Lamia Elgolli (L)

, Sousse, Tunisia.

Leila Ben Fatma (L)

Carcinology Department, Farhat HACHED Hospital, Sousse, Tunisia.

Slim Ben Ahmed (S)

Carcinology Department, Farhat HACHED Hospital, Sousse, Tunisia.

Mohamed Msaddak Azzouz (MM)

Gastroenterology Department, Mohamed Taahar Maamouri Hospital, Nabeul, Tunisia.

Olfa Hellara (O)

Gastroenterology Department, Fatouma Bourguiba Hospital, Monastir, Tunisia.

Amine Elghali (A)

General Surgery Department, Farhat HACHED Hospital, Sousse, Tunisia.

Fathi Darbel (F)

, Sousse, Tunisia.

Karim Skandrani (K)

, Sousse, Tunisia.

Moncef Mokkni (M)

Cytology and Anatomopathology Department, Farhat HACHED Hospital, Sousse, Tunisia.

Ameni Gdissa (A)

Cytogenetic, Molecular Genetics and Human Reproduction Biology - Farhat, HACHED Hospital, Sousse, Tunisia.

Rached Ltaief (R)

General Surgery Department, Farhat HACHED Hospital, Sousse, Tunisia.

Ali Saad (A)

Cytogenetic, Molecular Genetics and Human Reproduction Biology - Farhat, HACHED Hospital, Sousse, Tunisia.

Fahmi Hmila (F)

General Surgery Department, Farhat HACHED Hospital, Sousse, Tunisia.

Moez Gribaa (M)

Cytogenetic, Molecular Genetics and Human Reproduction Biology - Farhat, HACHED Hospital, Sousse, Tunisia.

Hans Morreau (H)

Pathology Department, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH